Details for Patent: 8,962,829

Which drugs does patent 8,962,829 protect, and when does it expire?

Patent 8,962,829 protects TEMBEXA and is included in one NDA.

This patent has twenty-eight patent family members in fourteen countries.

Summary for Patent: 8,962,829

Title:	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Abstract:	The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.
Inventor(s):	Ware, Jr.; Roy Wendell (Raleigh, NC), Downey; Aaron Leigh (Durham, NC)
Assignee:	Chimerix, Inc. (Durham, NC)
Application Number:	14/512,335
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process;

Drugs Protected by US Patent 8,962,829

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,962,829

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014349103
Australia	2017202386
Australia	2017203315
Brazil	112016010862
Canada	2929593
China	105899215